Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Patients”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT06171789
What this trial is testing

PRO1107 in Patients With Advanced Solid Tumors

Who this might be right for
Endometrial CancerOvarian CancerTriple Negative Breast Cancer+3 more
Genmab 33
Testing effectiveness (Phase 2)Ended earlyNCT03225547
What this trial is testing

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsBreast Cancer
University of Chicago 24
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Not applicableNo Longer AvailableNCT03067935
What this trial is testing

Individual Patient Expanded Access-Glembatumumab Vedotin

Who this might be right for
Metastatic gpNMB Expressing Triple Negative Breast Cancer
Celldex Therapeutics
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808662
What this trial is testing

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Who this might be right for
TNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLC+4 more
Memorial Sloan Kettering Cancer Center 107
Testing effectiveness (Phase 2)Study completedNCT02301988
What this trial is testing

Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 151
Testing effectiveness (Phase 2)UnknownNCT05402722
What this trial is testing

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Beijing 302 Hospital 30
Very early researchLooking for participantsNCT04265872
What this trial is testing

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Who this might be right for
Breast Cancer
Baylor Research Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT05113966
What this trial is testing

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06963905
What this trial is testing

Saci Nivo Rela for TNBC

Who this might be right for
Metastatic Triple-negative Breast Cancer
Yale University 60
Not applicableStudy completedNCT02247037
What this trial is testing

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai 68
Large-scale testing (Phase 3)Not Yet RecruitingNCT04301739
What this trial is testing

To Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Shanghai Henlius Biotech 522
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Early research (Phase 1)Study completedNCT01676753
What this trial is testing

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Who this might be right for
Advanced or Metastatic Breast CancerTriple Negative Breast Cancer
Jo Chien 32
Early research (Phase 1)Study completedNCT01969643
What this trial is testing

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Who this might be right for
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more
Seagen Inc. 290
Testing effectiveness (Phase 2)Study completedNCT03464942
What this trial is testing

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Peter MacCallum Cancer Centre, Australia 54
Early research (Phase 1)Study completedNCT05082610
What this trial is testing

HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Who this might be right for
CancerTumor, SolidNonsmall Cell Lung Cancer+4 more
Hummingbird Bioscience 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Testing effectiveness (Phase 2)Study completedNCT02460224
What this trial is testing

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid Tumors
Novartis Pharmaceuticals 490
Next Page